IMMIX BIOPHARMA, INC.: investing cash flow
Investing cash flow for IMMIX BIOPHARMA, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All IMMIX BIOPHARMA, INC. financial histories
What this measure means
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
Exact concept: us-gaap:NetCashProvidedByUsedInInvestingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2021-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -7,213,785 | USD | 2026-03-27 | 10-K/A · 0001493152-26-013298 |
| 2024-01-01 | 2024-12-31 | -1,177,680 | USD | 2026-03-27 | 10-K/A · 0001493152-26-013298 |
| 2023-01-01 | 2023-12-31 | -52,089 | USD | 2025-03-25 | 10-K · 0001641172-25-000387 |
| 2021-01-01 | 2021-12-31 | -802 | USD | 2023-03-27 | 10-K · 0001493152-23-009091 |
Related financial histories
- IMMIX BIOPHARMA, INC.: total assets
- IMMIX BIOPHARMA, INC.: total liabilities
- IMMIX BIOPHARMA, INC.: stockholders equity
- IMMIX BIOPHARMA, INC.: cash and cash equivalents
- IMMIX BIOPHARMA, INC.: net income or loss
- IMMIX BIOPHARMA, INC.: operating cash flow
- IMMIX BIOPHARMA, INC.: capital expenditure payments
- IMMIX BIOPHARMA, INC.: financing cash flow
- IMMIX BIOPHARMA, INC.: retained earnings or deficit
- IMMIX BIOPHARMA, INC.: basic weighted-average shares
- IMMIX BIOPHARMA, INC.: diluted weighted-average shares
- IMMIX BIOPHARMA, INC.: basic earnings per share
- IMMIX BIOPHARMA, INC.: diluted earnings per share
- IMMIX BIOPHARMA, INC.: income tax expense or benefit
- IMMIX BIOPHARMA, INC.: net property, plant and equipment
- IMMIX BIOPHARMA, INC.: share-based compensation expense
- IMMIX BIOPHARMA, INC.: operating income or loss
- IMMIX BIOPHARMA, INC.: current assets
- IMMIX BIOPHARMA, INC.: interest expense
- IMMIX BIOPHARMA, INC.: current liabilities
- IMMIX BIOPHARMA, INC.: current accounts payable
- IMMIX BIOPHARMA, INC.: operating expenses
- IMMIX BIOPHARMA, INC.: research and development expense
Inspect the source
- Entity
- IMMIX BIOPHARMA, INC. / CIK 0001873835
- Captured
- 2026-09-21T17:34:13.242Z
- SEC response SHA-256
a042a28a83d019d2522899064f6a9b74a10dc7c16d5e4f2133a259058f7c8420
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001873835.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))